Johnson & Johnson vs Vertex Pharmaceuticals Incorpor — Stock Comparison
Johnson & Johnson (JNJ) and Vertex Pharmaceuticals Incorpor (VRTX) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Vertex Pharmaceuticals Incorpor scores ahead of Johnson & Johnson on Q·Score (8.4 vs 7.1 out of 10), led by Health (9.2 vs 6.5) and Growth (7.4 vs 5.1). Analyst consensus targets imply greater upside for VRTX (+21.8%) than for JNJ (+7.3%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
High-quality business with 24% return on equity and 36% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs VRTX: which stock scores better overall?
Based on Q·Score, Vertex Pharmaceuticals Incorpor (VRTX) scores 8.4/10 versus Johnson & Johnson (JNJ) at 7.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or VRTX?
Vertex Pharmaceuticals Incorpor (VRTX) scores higher on Growth (7.4/10 vs 5.1/10). Johnson & Johnson reports revenue growth (9.9% YoY) while Vertex Pharmaceuticals Incorpor reports (7.8% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or VRTX more attractively valued?
Vertex Pharmaceuticals Incorpor (VRTX) scores higher on Valuation (7.8/10 vs 7/10). JNJ trades at 18.5× P/E versus VRTX at 21.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs VRTX?
There are 23 analysts covering JNJ with a consensus price target of $252.87, and 29 analysts covering VRTX with a consensus target of $548.69. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or VRTX?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 9.3/10). Net profit margin: JNJ at 21.8%, VRTX at 35.5%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or VRTX?
Vertex Pharmaceuticals Incorpor (VRTX) scores higher on Financial Health (9.2/10 vs 6.5/10). Market beta: JNJ at 0.26, VRTX at 0.31. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and VRTX?
Johnson & Johnson (JNJ) has a market capitalisation of $567.3B, while Vertex Pharmaceuticals Incorpor (VRTX) has a market cap of $114.3B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or VRTX pay dividends?
JNJ pays a dividend yield of 2.27%, while VRTX does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →